Esomeprazole potassium saltEsomeprazole potassium salt
MedChemExpress (MCE)
HY-17021B
161796-84-5
(S)-Omeprazole potassium salt
(-)-Omeprazole potassium salt
98.18%
-20°C, protect from light, stored under nitrogen *The compound is unstable in solutions, freshly prepared is recommended.
Room temperature in continental US
may vary elsewhere.
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
Esomeprazole (25-100 µM
20 hours
MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].
Esomeprazole (30-300 mg/kg
oral gavage
daily
for 19 or 11 days
C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].
H+, K+-ATPase[1][2] In Vitro Esomeprazole (25-100 µM
20 hours
MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Esomeprazole potassium salt Related Antibodies Cell Viability Assay[1] Cell Line: MDA-MB-468 cells
| | | |
| | | | | |
[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014
17(3):439-46. [Content Brief]
[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26
8:16. [Content Brief]
[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15
59(14):1333-9. [Content Brief]